⌘K
t
Tissue Regenix Group plc announced the posting of its Annual Report & Accounts and Notice of AGM, available on its website and posted in hard copy today, 27 June 2025. The Company's AGM will be held on 23 July 2025 at 1:00pm (BST). Additionally, the CEO and CFO will host an online presentation regarding final results on 1 July 2025 at 2pm (BST).
| Date | 27 Jun 2025 |
| Time | 07:00:08 |
| Category | AGMs and other meetings |
| ID | 6374O |
Tissue Regenix Group plc
('Tissue Regenix', the 'Group' or the 'Company')
Posting of Annual Report & Accounts
Notice of AGM
Tissue Regenix Group plc (AIM: TRX), the regenerative medical devices company, announces that the Annual Report and Accounts, notice of AGM, will be available later this morning on the Company's website, www.tissueregenix.com, in accordance with AIM Rule 20. For those who opted to receive hard copies of the Annual Report, these will be posted today.
The Company's AGM will be held at DLA Piper UK LLP, City Square House, 11 Wellington St, Leeds LS1 4DL on 23 July 2025 at 1:00pm (BST). Shareholders are invited to ask the Board questions about the Annual Report and Accounts or the AGM by email emailing Walbrook PR at TissueRegenix@walbrookpr.com.
The results of the votes on the proposed resolutions will be announced by RNS as soon as practicable after the conclusion of the AGM.
Investor Briefing
Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, will host a live online presentation relating to the final results via the Investor Meet Company platform at 2pm (BST) on Tuesday 1 July 2025. The presentation is open to all existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and register for the presentation here:
https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
For more information, please contact:
|
Tissue Regenix Group plc |
|
|
Daniel Lee, Chief Executive Officer David Cocke, Chief Financial Officer |
via Walbrook PR |
|
|
|
|
Cavendish Capital Markets (Nominated Adviser and Broker) |
|
|
Geoff Nash/Giles Balleny/Edward Whiley Nigel Birks - Life Science Specialist Sales Harriet Ward - ECM |
Tel: +44 (0) 20 7466 5000 |
|
|
|
|
Walbrook PR (Financial PR and IR) |
Tel: +44 (0)20 7933 8780 |
|
Alice Woodings / Lianne Applegarth |
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in regenerative medicine. The Company's patented decellularisation technology (dCELL®) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold that is not rejected by the patient's body and can be used to repair diseased or damaged body structures. Current applications address many crucial clinical needs in sports medicine, foot and ankle injuries, and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®. This biotech company specialises in regenerative medicine and is dedicated to developing high-quality, innovative tissue scaffolds to enhance healing opportunities in defects created by trauma and disease. CellRight's human tissue products may be used in spine, trauma, general orthopaedic, dental and ophthalmological surgical procedures.